Overview
Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
To show non-inferiority in the incidence rates of elevated calcium-phosphorus product between two treatment groups: 1) a group having an initial dose based on baseline PTH (baseline iPTH/80) and 2) a group having a starting dose based on body weight (0.04 mcg/kg).Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Abbott
Criteria
Inclusion Criteria:- Stage V Chronic Kidney Disease
- Patients on Hemodialysis requiring treatment for secondary hyperparathyroidism with
vitamin D therapy